Age-specific seroprevalence to varicella-zoster virus:: study in Swiss children and analysis of European data
Age-specific seroprevalence to varicella-zoster virus:: study in Swiss children and analysis of European data
复制标题
DOI：
10.1016/s0264-410x(01)00035-4
复制
发表时间：
2001-04-30
期刊：
影响因子：
5.5
通讯作者：
Mühlemann, K
中科院分区：
文献类型：
--
作者：
Aebi, C;Fischer, K;Mühlemann, K
最新的流行病学数据为欧洲潜在的水痘免疫策略提供了依据。本研究的范围是：（1）通过评价970例0 - 16岁个体血清中是否存在抗水痘带状疱疹病毒（VZV）IgG，生成新的血清阳性率数据;（2）审查现有的血清阳性率数据。在256名> 12岁的个体中，96.1%（95%，置信区间[CI]。93.7 - 98.5）为血清阳性。年龄> 12岁的瑞士公民血清反应阴性的可能性低于外国公民（2.3%比15.4%：比值比）。0.17; CI，0.05 - 0.58）。年龄特异性血清阳性率曲线显示7岁时达到峰值（84.9%，：CI，75.2 - 94.5），随后在8岁和9岁时降低。在所有先前报告的血清阳性率曲线中发现7 - 10岁的峰值（合并数据趋势的卡方检验）。P = 0.09：Poisson分析。P <0.001）。结论是：（1）在欧洲，> 90%的人在青春期前获得对VZV的免疫力;（2）没有证据表明最近原发性水痘的年龄上升;（3）血清阳性率可能存在从北到南的梯度。7 - 10岁时的峰值可能代表某些个体可检测抗体的短暂丧失。(C)2001爱思唯尔科技有限公司版权所有。
Up to date epidemiological data provide the rationale for potential varicella immunization strategies in Europe. The scope of this study was: (1) to generate new seroprevalence data by evaluating sera of 970 individuals aged 0-16 years for the presence of IgG against Varicella-zoster virus (VZV); and (2) to review existing seroprevalence data. Of 256 individuals > 12 years of age, 96.1% (95%, confidence interval [CI]. 93.7-98.5) were seropositive. Swiss citizens > 12 years of age were less likely to be seronegative than foreign citizens (2.3 vs. 15.4%: odds ratio. 0.17; CI, 0.05-0.58). The age-specific seroprevalence curve demonstrated a peak at 7 years of age (84.9%,: CI, 75.2-94.5) followed by lower rates at 8 and 9 years. A peak at 7-10 years of age was found in all previously reported seroprevalence curves (chi (2)-test for trend of pooled data. P = 0.09: Poisson analysis. P < 0.001). It is concluded that: (1) > 90% of individuals in Europe acquire immunity against VZV before adolescence: (2) there is no evidence for a recent upward shift of the age at primary varicella; and (3) there may be a north-to-south gradient of seroprevalence. The peak at 7-10 years may represent a transient loss of detectable antibody by some individuals. (C) 2001 Elsevier Science Ltd. All rights reserved.